EBOS lifts revenue and statutory profit despite softer underlying earnings

EBOS Group Limited ( (AU:EBO) ) has provided an announcement.

EBOS Group reported a 13% rise in revenue from continuing operations to A$6.77 billion for the six months to 31 December 2025, while statutory net profit attributable to owners increased 13% to A$124.8 million. Underlying net profit from continuing operations slipped 4.3% to A$125.4 million as the company absorbed higher restructuring, site transition and M&A-related costs, though underlying EBITDA edged up 3.2%, highlighting resilient operating performance amid ongoing integration activity.

The board declared a final dividend of NZ$0.57 per share, with net tangible assets per security marginally improving to negative A$4.30, reflecting the group’s substantial intangible and lease-related asset base. The reconciliation from reported to underlying earnings shows that acquisition accounting, restructuring charges and acquisition-related gains remain key drivers of the gap between statutory and underlying results, offering investors a clearer view of the business’s core profitability trajectory.

The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is a diversified healthcare and pharmaceutical distributor operating across Australasia. The company provides wholesale distribution, logistics and related services for medicines and healthcare products, serving pharmacies, hospitals and other healthcare providers in Australia and New Zealand.

Average Trading Volume: 136,505

Technical Sentiment Signal: Sell

Current Market Cap: A$4.29B

For detailed information about EBO stock, go to TipRanks’ Stock Analysis page.